Education
About Us
Working with TipRanks
Follow Us
CSL Limited (AU:CSL)
:CSL
CSL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$246.20 - AU$313.55
Previous CloseN/A
Volume375.76K
Average Volume (3M)909.67K
Market Cap
AU$124.77B
Enterprise ValueAU$156.94B
Total Cash (Recent Filing)$728.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)29.9
Beta0.41
Next Earnings
Aug 19, 2025EPS Estimate
3.75Last Dividend Ex-Date
Mar 10, 2025Dividend Yield1.8%
Share Statistics
EPS (TTM)8.60
Shares Outstanding484,212,130
10 Day Avg. Volume892,477
30 Day Avg. Volume909,673
Financial Highlights & Ratios
PEG Ratio3.29
Price to Book (P/B)N/A
Price to Sales (P/S)8.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.76
Enterprise Value/Ebitda16.46
Forecast
1Y Price Target
AU$331.15Price Target Upside28.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
CSL News
PremiumCompany Announcements
CSL Monitors U.S. Tariff Developments to Safeguard Medicine Access
PremiumCompany Announcements
CSL Limited Announces Director’s Share Acquisition
PremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Limited Updates Dividend Distribution Details
PremiumCompany Announcements
CSL Limited Issues Unquoted Equity Securities Under Employee Incentive Scheme
PremiumCompany Announcements
CSL Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
CSL Limited Issues Unquoted Equity Securities for Employee Incentive---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
5.00%
Mutual Funds
0.03% Other Institutional Investors
87.22% Public Companies and
Individual Investors
CSL FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest share price was AU$246.20 and its highest was AU$313.55 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is AU$124.77B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 19, 2025 which is in 136 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 11, 2025. The company reported AU$6.799 earnings per share for the quarter, missing the consensus estimate of AU$6.995 by -AU$0.197.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Undervalued.
Does CSL Limited pay dividends?
CSL Limited pays a Annually dividend of AU$2.071 which represents an annual dividend yield of 1.8%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate is 3.75.
How many shares outstanding does CSL Limited have?
CSL Limited has 484,212,130 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of AU$6.799 in its last earnings report, missing expectations of AU$6.995. Following the earnings report the stock price went down -0.265%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in AU:CSL
---
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$331.15 (28.51% Upside)
AU$331.15 (28.51% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $31.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.89%
12-Months-Change
Fundamentals
Return on Equity
15.38%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
---
CSL Company Deck
---
CSL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment, with strong financial performance led by CSL Behring and a promising outlook despite challenges in CSL Seqirus and specialty products due to external market conditions.Read More>---
CSL Stock 12 Month Forecast
Average Price Target
AU$331.15
▲(28.51% Upside)
Technical Analysis
Ansell
―
Cochlear Limited
―
Ramsay Health Care
―
Sonic Healthcare Limited
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Best Analysts Covering CSL
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-3.67%
reiterated a buy rating 9 days ago
Copying David Bailey's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -3.67% per trade.
---